Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

Kristie A. Blum, MD, Donn Young, PhD, Sarah Broering, Margaret S. Lucas, Thomas S. Lin, MD, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2833.

https://doi.org/10.1182/blood.V108.11.2833.2833

Published: 2006

Journal Articles

Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma.

Kristie A. Blum, MD, Margaret S. Lucas, Jeffrey S. Johnston, PhD, James Dalton, PhD, Donn Young, PhD, Robert A. Baiocchi, MD, PhD, Thomas S. Lin, MD, PhD, Pierluigi Porcu, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2768.

https://doi.org/10.1182/blood.V108.11.2768.2768

Published: 2006

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Jennifer Swenor, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Carolyn M. Cheney, MS, David M. Lucas, PhD, Donn Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3469.

https://doi.org/10.1182/blood.V104.11.3469.3469

Published: 2004

Journal Articles

Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.

Xiaobin B. Zhao, MS, Sabyasachi Biswas, PhD, Andrew Mone, MD, PhD, Jeffrey Ledbetter, PhD, Martha Hayden Ledbetter, PhD, Laura Grosmaire, PhD, Erik Espling, PhD, Carolyn Cheney, Donn Young, PhD, Robert J. Lee, PhD, Natarajan Muthusamy, PhD, John C. Byrd, MD

Blood (2004) 104 (11): 2515.

https://doi.org/10.1182/blood.V104.11.2515.2515

Published: 2004

Journal Articles

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Sherif S. Farag, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Donn Young, John C. Byrd

Blood (2004) 103 (4): 1472–1474.

https://doi.org/10.1182/blood-2003-07-2548

Published: 2004

NARROW

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma.

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma.

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only